At a glance
- Originator Ligand Pharmaceuticals
- Developer Cleveland Clinic
- Class Antineoplastics; Antipsoriatics; Benzoic acids; Naphthalenes; Retinoids; Skin disorder therapies; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor agonists; Protein synthesis inhibitors; Retinoic acid receptor agonists; Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 07 Dec 2018 Discontinued - Phase-II for Alzheimer's disease (In the elderly) in USA (PO)
- 01 Dec 2014 The Cleveland Clinic, Ohio, completes the BEAT-AD phase II trial in Alzheimer's disease (In the elderly) in USA (NCT01782742)
- 11 Feb 2014 ReXceptor plans a phase I trial in Healthy volunteers in USA (NCT02061878)